US-Werte, die Montag interessant werden könnten

 

Was bedeutet eigentlich dieses seltsame up, schon so oft gelesen.

Gruss E.



 

 

Dow Jones Business News
Daktronics 3Q Net 10c A Diluted Shr Vs Loss 2c
Wednesday February 19, 1:10 pm ET

Daktronics Inc. (NasdaqNM:DAKT - News) - Brookings, S.D.
  3rd Quar Feb. 1:
                       2003             2002
Sales                $38,220,000      $30,863,000
Net income             1,888,000         (293,000)
Avg shrs (diluted)    19.697,000       19,208,000
Shr earns
Net income                  .10             (.02)

Figures in parentheses are losses.

Daktronics Inc.'s third-quarter earnings beat the Thomson First Call (News - Websites)
consensus estimate of 6 cents a share.

In November, the maker of display systems said it expected third-quarter earnings of 5 cents to
11 cents a share, on sales of $36 million to $41 million.

Backlog at the end of the quarter stood at about $51 million, compared with about $30 million a
year earlier.


                   ·

 

Wenn denn die Nasi mitspielt...





 

 

http://chart.bigcharts.com/bc3/quickchart/...=203&mocktick=1&rand=818  

Digene High-Risk HPV DNA Test Approved by the FDA For Adjunctive Screening in Women Age 30 and Older
       TUESDAY, APRIL 01, 2003 7:05 AM
- PR Newswire

GAITHERSBURG, Md., Apr 01, 2003 /PRNewswire-FirstCall via Comtex/ -- Digene Corporation (DIGE) today announced that the U.S. Food and Drug Administration (FDA) has approved Digene's Pre-Market Approval Supplement (PMAS) application for its hc2(TM) High-Risk (HR) HPV DNA Test for use with a Pap test to adjunctively screen women age 30 and older to assess the presence or absence of high risk HPV types. The FDA's decision allows Digene to market its HPV Test with the Pap test for this screening indication.

Evan Jones, Digene's Chairman and Chief Executive Officer, stated, "This decision represents a major advancement in the fight against cervical cancer, offering women and their physicians the first objective screening measure of a woman's risk for cervical cancer. We are extremely excited by the FDA's decision. With our hc2 HR HPV Test, when used in conjunction with the Pap test, doctors can detect cervical disease and its precursors earlier than ever before."

Mr. Jones continued, "This is a monumental achievement for Digene, underscoring our leadership in the field of cervical cancer detection and prevention, and expanding our potential U.S. target market from approximately 3 million annual tests to approximately 30-35 million annual tests. The sensitivity and negative predictive value of our hc2 HR HPV Test should improve the quality of cervical cancer screening in the United States and around the world. Building on the momentum generated by the new guidelines published by the American Cancer Society (ACS) in November 2002 -- which recommend consideration of the combination of HPV DNA testing for high risk HPV types, together with a Pap test, as a primary cervical cancer screen following FDA approval -- we look forward to an initial launch of the new indication for the High-Risk HPV DNA Test in the U.S. this spring and a full scale launch in the third calendar quarter of 2003."

A recent editorial in The New England Journal of Medicine described the necessary association of HPV to cervical cancer and the role the addition of HPV DNA testing may play in cervical cancer screening and prevention. The editorial stated, "The discovery that persistent, oncogenic HPV infection is necessary for the development of cervical cancer is revolutionizing our approaches to screening and prevention, because an obvious corollary is that the absence of infection means that the risk of cancer is negligible."

Digene believes adjunctive screening to assess the presence or absence of high-risk HPV types represents a $400 million market potential in the United States. The Company believes it has in-place the necessary infrastructure to launch its test for this new indication and begin market development so that all appropriate women and health care providers are educated on the uses and benefits of the High-Risk HPV DNA Test for use in conjunction with the Pap test. Currently, approximately 50% of U.S. women with ASC-US Pap test results are tested with Digene's hc2 HPV Test as a follow-up to their abnormal Pap through a network of 270 laboratories that offer the Company's HPV Test. Reimbursement for this ASC-US indication is currently available for approximately 90% of the U.S. population with health insurance. Digene expects to work with these laboratories and payor organizations to permit access and reimbursement for the expanded indication. Digene has been working with the FDA for more than 2 years on this indication, and studies leading to approval took up to 10 years to complete.


 

Digene ist mir auch aufgefallen, zu GERN brauchen wir nix mehr schreiben.

SANG springt mir immer wieder ins Auge, haben ein profitables Jahr gemeldet, einen neuen CEO, kommen kräftig zurück seit Wochen , aktuell um 11 Dollar.

http://chart.bigcharts.com/bc3/quickchart/...398&mocktick=1&rand=548"

Gruss E.

SangStat Reports 2002 Revenues of $120.1 Million and Its First Fully Profitable Year  


FREMONT, Calif., Feb 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- SangStat
Medical Corporation (Nasdaq: SANG) today reported total worldwide revenues for
fiscal year (FY) 2002 of $120.1 million and its first fully profitable year.
Total revenues in the fourth quarter reached $31.7 million. Sales of its leading
immunosuppressive antibody, Thymoglobulin(R) (anti-Thymocyte globulin, rabbit),
were $55.2 million in North America (NA) for FY 2002 with record sales in the
fourth quarter of $16.6 million.

"With 120 million dollars in revenue, profitability and a strong balance sheet,
SangStat has many qualities investors look for in today's market," said Rick
Murdock, Interim Chairman, President and CEO. "2003 should be another successful
year for SangStat with several opportunities for continued growth."

SangStat generated $1.3 million in net income in the fourth quarter of 2002 and
made an equity investment in THP of $3.2 million. In total, SangStat ended the
fourth quarter of 2002 with available cash and cash equivalents of $97.5 million
and outstanding, long-term debt of $15.9 million.

SangStat has become a profitable biotech company with full year 2002 earnings
per share (EPS) of $0.24 and 2003 EPS projected to increase to $0.35 - $0.45
(see 2003 financial guidance below). Fourth quarter EPS of $0.05 was lower than
expected and reflects certain downward adjustments and one-time SG&A expenses.
Downward adjustments included expenses related to SangStat's collaboration with
Therapeutic Human Polyclonals, Inc. (THP) announced on November 11, 2002 (impact
of approximately $0.7 million) and lower than expected sales resulting from a
possible destocking of Gengraf(TM) (cyclosporine capsules) (impact of
approximately $0.9 million). In addition, one-time SG&A expenses including
management re-structuring costs in Europe and a provision for a doubtful
receivable in Italy reduced fourth quarter EPS by approximately $0.7 million.
Downward adjustments in EPS were partially offset by better than expected sales
of Thymoglobulin (impact of approx. $0.5 million). In total, these adjustments
reduced earnings by approximately six cents per share.

Selling, general and administrative expenses were $10.3 million in the fourth
quarter of 2002 compared to $8.8 million in the third quarter of 2002 and $8.3
million in the fourth quarter of 2001. Research and development expenses,
including discovery research, regulatory, and clinical expenses, were $5.0
million in the fourth quarter of 2002 versus $4.4 million in the third quarter
of 2002 and $4.2 million for the fourth quarter of 2001. Increased R&D spending
in the fourth quarter was aimed at supporting the Company's promising
development programs and included payment of a technology access fee to THP.

Overall, SangStat's financial results for 2002 exceeded most analysts'
assessments from earlier in the year. In February 2002, shortly after a
successful public offering, analysts' consensus estimates for 2002 revenues and
EPS were $116.2 million and $0.20 respectively. All financial results are
subject to change based on full audit and review.

2003 Financial Guidance

SangStat has decided to change the way it gives financial guidance. In the past,
SangStat provided quarterly revenue and earnings per share (EPS) guidance for
the ensuing quarter during the earnings announcement for the preceding quarter.
Going forward, SangStat instead will provide full year, 2003, estimated revenue
ranges for Thymoglobulin in North America, Gengraf, combined European/Rest of
World sales, other revenue, total projected annual revenue and full year EPS.
SangStat also intends to supplement this guidance with product and market
assessments from time to time, consistent with the Securities and Exchange
Commission's (SEC) regulations on Fair Disclosure. The following chart outlines
SangStat's current 2003 financial guidance.







 

Nach Ausbruch aus der Tradingrange und neuem 52-W-Hoch ist TWTC heute ins Depot aufgenommen worden.